<br>        Inclusion Criteria:<br><br>          1. Caucasian males and females, 21-55 years of age<br><br>          2. Body mass index (BMI) 18.5-29.9 kg/m2<br><br>          3. Generally in good health without clinically significant findings at screening<br><br>          4. No chronic fatigue syndrome according to the Fukuda Centres for Disease Control and<br>             Prevention (CDC) criteria at screening<br><br>          5. Subjective feeling of chronic stress and tiredness for 3-12 last months prior to<br>             screening<br><br>          6. Screening Scale of Chronic Stress (SSCS) score >18<br><br>          7. Fatigue Severity Scale score >4<br><br>          8. = 3 cups/portions of coffee and/or caffeine-containing food/beverages per day in the 3<br>             last months prior to screening and during the study<br><br>          9. Regular stable continuous level of daily activities<br><br>         10. Regular sleep-wake cycle<br><br>         11. Normal dietary habits according to investigator's judgement<br><br>         12. = moderate level of physical exercise<br><br>         13. Readiness to comply with study procedures, in particular:<br><br>               -  Consumption of the IP during the treatment period<br><br>               -  Filling in all questionnaires<br><br>               -  Keep habitual diet and level of physical exercise<br><br>         14. No change in smoking habits during the study<br><br>         15. Women of child-bearing potential only:<br><br>               1. negative pregnancy testing (ß-HCG in urine at screening)<br><br>               2. commitment to use reliable contraception methods during the entire study<br>                  Participation is based upon written informed consent form (ICF) by the<br>                  participant following written and oral information by the investigator regarding<br>                  nature, purpose, consequences and possible risks of the clinical study.<br><br>        Exclusion Criteria:<br><br>          1. Known sensitivity to any components of the IP<br><br>          2. Any medical condition associated with tiredness (e.g. iron deficiency, hypotension<br>             etc.)<br><br>          3. History and/or presence of clinically significant disease, which per investigator's<br>             judgement could interfere with the results of the study or the safety of the subject:<br><br>               1. Psychiatric diseases, e.g. depression, schizophrenia<br><br>               2. Eating disorders such as anorexia<br><br>               3. Untreated or non-stabilized metabolic diseases, e.g. diabetes mellitus<br><br>               4. Untreated or non-stabilized thyroid disorder<br><br>               5. Untreated or non-stabilized hypertension (systolic blood pressure =140 mmHg<br>                  and/or diastolic blood pressure =90 mmHg)<br><br>               6. Significant gastrointestinal diseases<br><br>               7. Insomnia<br><br>               8. Known bleeding disorders such as haemophilia<br><br>               9. Any other known significant or serious condition / disease that renders subjects<br>                  ineligible (e.g. history of malignancy within the past 5 years prior to<br>                  screening, any clinically significant cardiovascular, renal, liver disease etc.)<br><br>          4. Use of medication which in the investigator's judgement could interfere with the<br>             results of the study (e.g. psychoactive medication, statins, proton pump inhibitors,<br>             blood-pressure medications, antihistamines, antibiotics, diuretics) within the last 4<br>             weeks prior to screening and during the study<br><br>          5. Consumption of vitamins, nutritional supplements, supplementary balanced diet, mineral<br>             products which in the investigator's judgement could interfere with the results of the<br>             study within last 4 weeks prior to screening and during the study<br><br>          6. Consumption of adaptogens (e.g. ginseng or Schisandra) or St. John's Wort within last<br>             4 weeks prior to screening and during the study<br><br>          7. Consumption of energy drinks during the study<br><br>          8. Start of use of contraception medication during the last 3 months prior to screening<br>             and during the study<br><br>          9. Use of anticoagulants such as warfarin<br><br>         10. Clinically significant deviation of laboratory parameters and/or deviations > 2 x ULN<br>             (upper limit of normal) at screening<br><br>         11. Recent or current significant stressors (e.g. active grieving)<br><br>         12. Chronic pain<br><br>         13. Chronic sleep deficiency (< 5 hours/night)<br><br>         14. Alcohol abuse (men: =21 units/week, women: =14 units/ week; 1 unit equals<br>             approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits)<br><br>         15. Drug abuse<br><br>         16. Participation in another study during the last 30 days prior to screening<br><br>         17. Women of child-bearing potential: pregnant or breastfeeding<br><br>         18. Any situation expected during the study causing acute high level of stress<br><br>         19. Any other reason deemed suitable for exclusion as per investigator's judgment, e.g.<br>             insufficient compliance with study procedures<br>